ANDA 207108, held by Pai Holdings. Hydromorphone Hydrochloride.
As of Nov 16, 2026, ANDA 207108 (Hydromorphone Hydrochloride), held by Pai Holdings, was first approved by FDA on Apr 22, 2020, with 2 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 22, 2020 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Hydromorphone Hydrochloride5MG/5ML ยท solution;oral | Hydromorphone Hydrochloride | Discontinued |
| Jun 18, 2026 | Supplement 5REMS | Approved | None posted |
| Nov 19, 2024 | Supplement 2REMS | Approved | None posted |
| Apr 22, 2020 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters